UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.9100+0.0410 (+4.72%)
At close: 04:00PM EDT
0.9300 +0.02 (+2.20%)
After hours: 05:31PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 47.50M
Enterprise value -47.17M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.24
Price/book (mrq)0.83
Enterprise value/revenue -2.25
Enterprise value/EBITDA 0.40

Trading information

Stock price history

Beta (5Y monthly) 0.69
52-week change 3-82.23%
S&P500 52-week change 329.57%
52-week high 35.2000
52-week low 30.5000
50-day moving average 30.7332
200-day moving average 31.6262

Share statistics

Avg vol (3-month) 3749.26k
Avg vol (10-day) 3517.47k
Shares outstanding 554.66M
Implied shares outstanding 654.66M
Float 839.35M
% held by insiders 114.59%
% held by institutions 145.56%
Shares short (15 Mar 2024) 42.48M
Short ratio (15 Mar 2024) 42.32
Short % of float (15 Mar 2024) 46.33%
Short % of shares outstanding (15 Mar 2024) 44.54%
Shares short (prior month 15 Feb 2024) 42.23M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,085.45%

Management effectiveness

Return on assets (ttm)-49.29%
Return on equity (ttm)-109.80%

Income statement

Revenue (ttm)20.97M
Revenue per share (ttm)0.39
Quarterly revenue growth (yoy)-7.90%
Gross profit (ttm)N/A
EBITDA -121.24M
Net income avi to common (ttm)-118.51M
Diluted EPS (ttm)-2.1900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)100.76M
Total cash per share (mrq)1.84
Total debt (mrq)43.17M
Total debt/equity (mrq)75.62%
Current ratio (mrq)4.54
Book value per share (mrq)1.05

Cash flow statement

Operating cash flow (ttm)-92.08M
Levered free cash flow (ttm)-52.53M